🎉 Happy New Year from Plus Therapeutics! 🎉
As we ring in the new year, we want to extend our heartfelt gratitude to the patients, medical staff, and the entire cancer community who have supported our mission throughout 2024. Thanks to your dedication and hard work, we’ve made significant strides in our brain cancer clinical trials, with 52 ReSPECT-GBM Recurrent Glioblastoma patients and 29 ReSPECT-LM Leptomeningeal Metastases patients treated to date.
Your continued support and participation are instrumental in advancing our efforts to improve outcomes for patients battling glioblastoma, leptomeningeal metastases, and other brain cancers.
A Look Back: Progress in 2024
2024 was a year of progress in the field of neuro-oncology, with important milestones reached in our ReSPECT-GBM and ReSPECT-LM clinical trials. These trials are designed to offer innovative treatments to patients with recurrent glioblastoma (GBM) and leptomeningeal metastases (LM)—two of the most challenging and aggressive forms of brain cancer.
- 52 ReSPECT-GBM patients treated for recurrent glioblastoma (total since trial start)
- 29 ReSPECT-LM patients treated for leptomeningeal metastases (total since trial start)
These numbers represent more than just statistics—they are the stories of patients and their families who have shown incredible strength in the face of adversity. Together, we are making progress in the fight against these devastating diseases.
Looking Ahead to 2025: New Year, New Opportunities
As we look ahead to 2025, we are excited about the continued progress of our clinical trials and the potential to bring new treatment options to more patients in need. The fight against glioblastoma and leptomeningeal metastases continues, and we remain committed to exploring innovative therapies that can make a meaningful difference in the lives of those affected.
Thank You for Your Support
To all the patients, caregivers, researchers, and healthcare providers involved in our trials: we couldn’t do this without you. Your commitment to advancing brain cancer research is helping us pave the way for better treatments and outcomes for future patients.
We look forward to another year of progress, hope, and collaboration in 2025. Together, we will continue to push forward in the fight against glioblastoma and brain cancer.
Stay Connected for Updates:
If you want to stay informed about the latest updates on our clinical trials, new advancements in neuro-oncology, and other important news, be sure to visit our website regularly and follow us on social media.
- Visit our website: Plus Therapeutics
- Learn more about our ReSPECT clinical trials: ReSPECT Clinical Trials
Wishing you all a happy new year filled with health, hope, and progress!
Recent Comments